Financials
| Final Results | Sep. 11, 2025 |
| Interim Results | Jan. 30, 2025 |
| Results Year Ended 30 April 2024 | Sep. 24, 2024 |
| Interim Results | Jan. 30, 2024 |
| Interim Results | Jan. 25, 2023 |
| Results for the year ended 30 April 2022 | Oct. 28, 2022 |
| Interim Results for the 6 months ended 31 Oct 2021 | Jan. 26, 2022 |
Proxies
| Result of Annual General Meeting | Oct. 25, 2024 |
| Notice of AGM | Oct. 01, 2024 |
| Result of AGM | Nov. 29, 2023 |
| Notice of AGM | Oct. 31, 2023 |
| Result of Annual General Meeting | Nov. 21, 2022 |
| Notice of AGM | Oct. 28, 2022 |
| Result of AGM | Nov. 23, 2021 |
Ownership Update
| Director Dealing | Sep. 16, 2025 |
| Director Dealing | Aug. 08, 2025 |
| Director/PDMR Shareholding | Aug. 04, 2025 |
| Director Dealing | May. 21, 2025 |
| Issue of share options | Feb. 20, 2025 |
| Holding(s) in Company | Oct. 24, 2024 |
| Issue of share options | May. 21, 2024 |
Announcements
| Notice of Results | Sep. 04, 2025 |
| Strong Phase 2 data on iSCIB1+ in Melanoma | Jul. 22, 2025 |
| Share Option Exercise | Jul. 16, 2025 |
| Scancell initiates new arm in SCOPE Phase 2 study | Jun. 25, 2025 |
| Partnership with NHS Cancer Vaccine Launch Pad | Apr. 14, 2025 |
| Scancell to present at 2025 AACR Annual Meeting | Apr. 01, 2025 |
| Scancell presenting at AACR IO conference | Feb. 17, 2025 |